J&J Will Turn To Clinical Evidence To Overcome Reimbursement Challenges
This article was originally published in The Pink Sheet Daily
Executive Summary
Reimbursement challenges in 2005 slowed adoption of Johnson & Johnson's injectable extended-release antipsychotic Risperdal Consta, the company reported Jan. 24